Price Alert: Shares of PMV (PMVP) Trade 9.77% Higher at Midday May 13
Equities Staff Follow |PMV Pharmaceuticals Inc (NASDAQ: PMVP) shares climbed 9.77%, or $1.195 per share, as on 12:06:40 est today. After Opening the Day at $12.69, 118,492 shares of PMV have been traded today and the stock has ranged between $13.43 and $12.52.
Already the company has moved YTD 47.06%.
PMV anticipates its next earnings on 2022-08-12.
For technical charts, analysis, and more on PMV visit the company profile.
About PMV Pharmaceuticals Inc
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
To get more information on PMV Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: PMV Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer